1. EMA.(Draft XXIII) Guideline on the pharmacokinetic and clinical evaluation of modified‐release dosage forms. EMA/CHMP/EWP/280/96 Rev1. London 21 February2013.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140482.pdf[28 February 2014].
2. EUFEPS BABP Network Open Discussion Forum: Revised European Guideline on Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms. 17–18 June 2013 in Bonn Germany.https://custom.cvent.com/6E33084F71EB4DD6B892656072736BFB/files/2d4231a4d943496194dd6e258bfdc843.pdf[28 February 2014].
3. EUFEPS BABP Network Open Discussion Forum: Revised European Guideline on Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms. 17–18 June 2013 in Bonn Germany. Session III: Specific issues for BE assessment by Alfredo García Arieta AEMPS Madrid ES.https://custom.cvent.com/6E33084F71EB4DD6B892656072736BFB/files/07323e6d219f47cdae68e89f1f508b6b.pdf[28 February 2014].
4. Ueber die Bedingungen fuer die Akkumulation indifferenter Narkotika. Theoretische Berechnungen;Widmark EMP;Biochem Z,1924